Phil,
I had the 36 rounds to the prostate bed plus a six-month Lupron Depot shot after a biochemical recurrence in 2023. My initial diagnosis was July 2020, Gleason 8 followed by a radical prostatectomy in January 2021. We decided against spot radiation to the single lymph node based on the clinical trial below:

Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial
Piet Ost, Shankar Siva, Sigmund Brabrand, Piet Dirix, Nick Liefhooghe, François-Xavier Otte, Alfonso Gomez-turriaga, Wouter Everaerts, Mohamed Shelan, Antonio Conde-Moreno, Fernando López Campos, Alexandros Papachristofilou, Matthias Guckenberger, Marta Scorsetti, Almudena Zapatero, Ana-Elena Villafranca turre, Clara Eito, Felipe Couñago, Paolo Muto, Wim Duthoy, Nicolas Mach, Valérie Fonteyne, Daniel Moon, Kristian Thon, Carole Mercier, Vérane Achard, Karin Stellamans, Els Goetghebeur, Dries Reynders, Thomas Zilli
Summary
Background Various locoregional treatments exist for PET-CT-detected pelvic nodal oligorecurrences in patients with Lanc prostate cancer. We aimed to assess whether elective nodal radiotherapy (ENRT) to the pelvis would be superior to metastasis-directed therapy (MDT).
Pub
Ma htt
S1
Methods PEACE V-STORM is a phase 2, open-label, randomised, controlled trial conducted in 21 hospitals in Australia, Belgium, Italy, Norway, Spain, and Switzerland. Eligible participants were aged 18 years or older, with WHO performance status 0-1 and a histologically confirmed initial diagnosis of adenocarcinoma of the prostate, with
D
a PET-detected pelvic nodal oligorecurrence (up to five nodes) following radical local treatment. Patients were randomly assigned (1:1) to MDT or ENRT. Randomisation was done online by minimisation with randomisation factor 0•80 and was stratified by type of PET tracer (choline vs prostate-specific membrane antigen) and type of MDT used (salvage lymph node dissection vs stereotactic body radiotherapy or simultaneous integrated boost). Participants and researchers were not masked to treatment assignment. Patients in the MDT group had salvage lymph node dissection or stereotactic body radiotherapy (30 Gy in three fractions every other day), with 6 months of androgen
in the ENDT aroun received a 45 Gy dose in 25 tractions to the pelvis in the pelvis in favor of more aggressive treatment.